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1. Introduction 
1.1 Trisomy 21 causes phenotypes associated with Down syndrome  
Down syndrome (DS) occurs in approximately 1 out of 700 live births and most commonly 
results from three copies of human chromosome 21 (Hsa21) (Christianson, 2006). DS is a 
multifaceted disorder with over 80 clinically defined phenotypes including those affecting 
the central nervous system, heart, gastrointestinal tract, skeleton and immune system 
(Epstein, 2001; Van Cleve and Cohen, 2006). Phenotypes associated with individuals with 
DS vary in both incidence and severity, leading to a vast array of phenotypic combinations 
among those with Trisomy 21 (Ts21) (Deutsch et al., 2005; Epstein, 2001; Van Cleve et al., 
2006; Van Cleve and Cohen, 2006). For example, cognitive impairment, hypotonia and 
craniofacial features are universal phenotypes, whereas cardiac abnormalities only affect 
approximately half of individuals with DS. Individual phenotypes similar to those seen in 
DS have been documented in individuals without Ts21, but a general higher incidence and 
severity of these phenotypes in individuals with DS suggests that trisomy plays an 
important role in initiating or modifying these features  (Epstein, 2001; Roper and Reeves, 
2006). Although it has been suggested that common mechanisms may be involved in similar 
phenotypes seen in individuals with and without Ts21, common pathophysiology must be 
proven for each individual phenotype. 
A chromosomal basis for DS was postulated as early as 1932 (Patterson and Costa, 2005). 
After Jerome Lejeune established that DS was caused by an extra Hsa21, he studied the 
metabolic pathways associated with Ts21 phenotypes in an attempt to cure DS (Neri and 
Opitz, 2009). Alternate causes of DS, including translocations and mosaicism of extra 
material from Hsa21, were established shortly after the chromosomal basis of DS had been 
discovered (Patterson and Costa, 2005). These early genetic findings set the stage for current 
paradigms and research surrounding the gene-phenotype relationships in DS.  
Although ~95% of the incidence of DS is due to trisomy of the entire Hsa21, DS also results 
from extra genetic material from Hsa21 translocated to other chromosomes. Additionally, 
some individuals with DS phenotypes have Ts21 in only a portion of their cells (mosaicism). 
Differences in genetic and cellular composition of the trisomy may lead to the observed 
differences in DS phenotypic incidence and severity. Genotypic and phenotypic variations 
have also been used to hypothesize about trisomic genes or chromosomal regions that may 
cause or significantly alter DS phenotypes. Such genotype-phenotype correlations are 
important in defining the etiology of traits associated with DS as well as suggesting possible 
therapeutic mechanisms to overcome deficits seen in individuals with DS.  
www.intechopen.com
 
Genetics and Etiology of Down Syndrome 66
1.2 Hypotheses regarding genotype-phenotype correlation in DS 
Early investigations into the genotype-phenotype relationship drew upon information from 
individuals with partial Ts21. By examining these individuals, determining the extra 
chromosomal material and corresponding phenotypes, an early causal hypothesis linked DS 
to trisomy of the distal end of Hsa21 (Patterson and Costa, 2005). A reductionist variation of 
this hypothesis later stated that individual phenotypes and features could be mapped to 
specific regions of the genome, and the addition of these regions with their respective 
phenotypes would cause the multitude of traits associated with DS (Neri and Opitz, 2009). 
Others had a more global or genomic view of the genotype-phenotype relationship and 
hypothesized that DS phenotypes were due to a general genomic imbalance initiated by 
Ts21. Many new ideas have extended or combined previous hypotheses as well as proposed 
novel views about the correlation between genes and phenotypes in DS, especially with an 
increased ability to precisely define the genotypes and phenotypes associated with DS. Yet, 
the exact mechanisms of how the triplication of genes on Hsa21, the smallest and least gene 
dense of the autosomes, causes one of the myriad phenotypes associated with DS have still 
largely not been established. One or more of the hypothesized mechanisms may be correct 
for a single phenotype associated with DS, yet it is unlikely that a single overriding 
mechanism would describe the etiology of all Ts21 phenotypes (Epstein, 2001). 
1.2.1 Gene dosage imbalance hypothesis 
The “gene dosage imbalance” hypothesis suggests that an increased dosage or copy number 
of genes on Hsa21 would lead to an increase in gene expression and protein product in the 
individual (Antonarakis et al., 2004; Epstein, 2001; Pritchard and Kola, 1999). In essence, 
overexpression of the products of dosage sensitive genes on Hsa21 would lead to DS 
phenotypes. This hypothesis has been extended to include the possibility that specific genes 
or subsets of genes may control specific DS phenotypes (Patterson, 2007). Most studies have 
concluded that three copies of Hsa21 genes leads to an average 50% higher expression of 
trisomic genes as compared to euploid (normal chromosomal complement) individuals 
(Gardiner et al., 2010). As additional high throughput analyses are performed, however it is 
becoming increasingly clear that the gene expression changes may be specific to a group of 
genes in a particular tissue at a precise developmental or mature stage. Additionally, some 
trisomic gene expression changes may overlap with normal expression of these genes in the 
euploid chromosomal component (Ait Yahya-Graison et al., 2007; Prandini et al., 2007; 
Wiseman et al., 2009).  
1.2.2 Amplified developmental instability hypothesis 
The “amplified developmental instability” hypothesis states that a non-specific dosage of a 
number of trisomic genes leads to a genetic imbalance that causes a large impact on the 
expression and regulation of many genes throughout the genome (Pritchard and Kola, 1999; 
Shapiro, 1983). This disruption in genetic homeostasis or more generalized change in gene 
expression throughout the genome would affect signaling pathways and lead to phenotypes 
associated with DS. Therefore, it has been hypothesized that traits in individuals with DS 
are not caused by the altered expression of a particular gene, but rather the general changes 
in expression throughout the genome caused by trisomy that lead to DS traits (Patterson, 
2009). An additional premise of this hypothesis is that the larger the number of trisomic 
genes, the higher the incidence and severity of DS phenotypes due to increased genetic 
instability. An extension of this hypothesis is that some phenotypic changes associated with 
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DS may not be attributable to specific genetic changes but rather to changes in the 
expression of the entire chromosomal domain (Gardiner et al., 2010). 
1.2.3 Critical region(s) hypothesis   
Phenotypic analyses conducted on individuals with partial trisomy for Hsa21 led to a 
hypothesis that only one or a few small chromosomal regions, termed “Down syndrome 
critical regions” (DSCR), contain genes responsible for the majority of DS phenotypes 
(Delabar et al., 1993; Korenberg et al., 1990). It has been suggested that DS (including many 
of the major, most well defined phenotypes) was caused by one specific DSCR (Epstein, 
2001). Even before the identification of specific genes on Hsa21, a region of 1.6-2.5 Mb on 
Hsa21was thought to be responsible and sufficient to cause most DS phenotypes (Dahmane 
et al., 1998; Ohira et al., 1996). The sequencing of Hsa21 proved to be an important factor in 
the progression of DS research (Hattori et al., 2000) and led to further insight into genotype-
phenotype correlations associated with DS and precise characterizations of DSCR regions 
(Patterson, 2009). A region of 3.8-6.5 Mb on 21q21.22 containing approximately 30 genes has 
been traditionally identified as the DSCR, although recent studies have demonstrated that 
this DSCR is not sufficient for all major DS phenotypes, though its inclusive genes may be 
relevant for some individual phenotypes (Delabar et al., 1993; Lyle et al., 2009). A current 
hypothesis states that certain chromosomal regions may contain a significant gene or genes 
necessary for the development or maintenance of specific but not all DS phenotypes (Korbel 
et al., 2009; Lyle et al., 2009; Olson et al., 2007).  
1.2.4 Other genetic, epigenetic and environmental considerations 
The hypotheses of how genetic mechanisms control DS phenotypes are not mutually 
exclusive, may include a combination of different mechanisms and may be unique for each 
particular phenotype. It is now believed that contributions to phenotypes associated with 
DS are likely to come from a number of genes. Variability in genomes may also come from 
allelic heterogeneity or other differences in the genetic architecture (Antonarakis et al., 
2004). There may be genes that have a larger effect on certain phenotypes (Epstein, 2001; 
Patterson, 2009), or genetic contributions may be additive, subtractive, or epistatic (Gardiner 
et al., 2010). Recently it has been shown that epigenetic modifications and allelic differences 
also play a significant role in the development of these phenotypes, not just the simple 
presence of the chromosomal imbalance (Belichenko et al., 2009; Elton et al., 2010). Other 
factors including environmental influences and stochastic events also add to the differential 
manifestation of phenotypes. 
1.2.5 Dosage compensation 
Extra copies of genes may be found as a result of a number of duplication events, yet many 
of the resultant trisomies may be difficult to detect or have subtle phenotypes. Though there 
may be an extra copy of a gene, and even alterations in gene expression with the resultant 
protein product, dosage imbalance for a specific gene may have no effect on a phenotype. 
Such genes have been “dosage compensated” by some mechanism (Antonarakis et al., 2004). 
Gene expression experiments of cells with Ts21 have shown that a high percentage of three 
copy genes may undergo dosage compensation (Ait Yahya-Graison et al., 2007). This 
compensation could be accomplished by gene regulatory networks or negative feedback 
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loops. Dosage compensation may be tissue or time dependent and may play an important 
role in the development and progression of DS phenotypes.  
1.3 Mouse models of DS to understand genotype-phenotype correlation 
In addition to being valuable tools for better understanding Ts21 and DS phenotypes, DS 
mouse models have also been utilized as predictive models of novel DS phenotypes (Baxter 
et al., 2000). Mice provide access to all tissues at all developmental stages, the ability to 
understand genetic and cellular mechanisms caused by trisomy, and a resource to 
understand potential treatments for phenotypes. Genes found on Hsa21 are highly 
conserved in order and homology on three different mouse chromosomes: mouse 
chromosome (Mmu)16, 17, and 10. Several DS mouse models have been created with 
segmental trisomy for different regions of the distal portion Mmu16, that contains nearly 
half the gene homologs found on Hsa21 (Hattori et al., 2000; Pletcher et al., 2001). The 
Ts65Dn mouse is the most commonly used DS model with segmental trisomy for the distal 
portion of Mmu16. Three copies of the region between Mrpl39 and Znf295 spanning 13.6 Mb 
on Mmu16 and containing over 100 Hsa21 gene homologs results in  several DS-like 
phenotypes (Reeves et al., 1995). The Ts1Cje mouse contains segmental trisomy for 
approximately 78% (Sod1-Znf295 excluding Sod1) of the triplicated genes in the Ts65Dn 
model (Olson et al., 2004b; Sago et al., 1998). Both Ts65Dn and Ts1Cje mice contain three 
copies of the putative DSCR region and exhibit a significant amount of phenotypic similarity 
to humans with DS. The Ts1Rhr/Ms1Rhr mouse models were created by generating a 3.9 
Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) homologous to those 
found in the most commonly defined human DSCR (Olson et al., 2004a). The 
transchromosomal Tc1 mouse model of DS has a copy of Hsa21 in its cells, though there are 
some deletions of Hsa21 regions and significant mosaicism in this model (O'Doherty et al., 
2005). The Ts1Yey model contains the entire region of Hsa21 homology on Mmu16 from 
D930038D03Rik-Znf295 duplicated on one Mmu16 and results in trisomy for this region in 
the mouse model (Li et al., 2007) (See Table 1). 
More recently, mouse models of DS have been made that contain small regions of homology 
from chromosomes other than Mmu16. The Ts1Yah model contains a duplication of Mmu17 
from Abcg1-U2af1 with homology to Hsa21 (Pereira et al., 2009). The Ts2Yey model has a 
duplication of the entire region of Mmu10 homologous to Hsa21 (Prmt2-Pdxk). The Ts3Yey 
mouse has a duplication of the entire Mmu17 chromosomal region that corresponds to 
Hsa21 (Abcg1-Rrp1b) (Yu et al., 2010). Mice containing entire regions of homology to Hsa21 
are being generated to examine DS phenotypes. Mouse models of DS may exhibit certain 
DS-like phenotypes with differing severity, but phenotypes may not be conserved across 
models, thus adding to the usefulness of the models for understanding the genotype-
phenotype relationships associated with DS. 
1.4 Using modern genetic and genomic tools to understand genotype-phenotype 
correlation in DS 
Because DS and its resultant phenotypes are caused by trisomy, the gene-phenotype 
correlation (the genes responsible for the cellular or developmental changes) is of great 
importance in understanding DS. DS may be viewed as a chromosomal disorder due to 
three copies of Hsa21, a genetic disorder resulting from the altered expression of trisomic 
genes, or a disorder that results from alterations in gene expression and pathways  
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Common 
Name 
Genetic triplication Number of triplicated 
genes 
Ts65Dn Ts(1716)65Dn 104 (Mmu 16) 
Ts1Rhr Dp(16Cbr1-Orf9)1Rhr 33 (Mmu 16) 
Ts1Cje Ts(1216C-tel)1Cje 81 (Mmu16) 
Tc1 Tc(Hsa21)1TybEmcf 131 (~92% of  Hsa 21) 
Ts1Yey Dp(16 D930038D03Rik-
Znf295)1Yey 
Mmu 16 
Ts2Yey Dp(10Prmt2-Pdxk)2Yey Mmu 10 
Ts3Yey Dp(17Abcg1-Rrp1b)3Yey Mmu 17 
Table 1. Common DS mouse models with defined trisomic regions.   
throughout the entire genome. Several studies have documented differential gene 
expression in tissues originating from varying spatial and developmental environments in 
attempts to determine genetic mechanisms affecting DS phenotypes (Conti et al., 2007; 
Lintas et al., 2010; Lyle et al., 2004; Moldrich et al., 2007). High throughput analysis utilizing 
tools such as microarray analysis, qPCR (quantitative polymerase chain reaction) and SAGE 
(serial analysis of gene expression) not only allow for a better understanding of gene 
expression aberrations in a spatiotemporal sense, but also permit for a better understanding 
of gene interactions within the context of natural physiological conditions. Though 
disparities exist between tissues and developmental time points, such analyses have 
provided insight into genes that appear to be critical to the development of specific DS 
phenotypes. New genetic information, coupled with precisely defined cellular and 
molecular phenotypes, (often using mouse models), has allowed the testing of multiple 
hypotheses concerning the gene-phenotype relationship. Functional groupings of 
dysregulated genes may add additional mechanistic insight into the origin of DS 
phenotypes, and such groupings may transcend both time and tissue type. The intersection 
of genetic and functional information may lead to new insights into the gene-phenotype 
relationship and the mechanisms leading to the development of DS phenotypes. With 
increasing ability to assess large scale gene expression, the importance of both trisomic and 
non-trisomic genes and genetic pathways utilizing gene products from the entire genome 
has been investigated. Instead of a simple notion of trisomy for Hsa21 causing a disorder or 
trisomic expression of specific genes on Hsa21 causing a disorder, current technologies and 
techniques now suggest that DS, with its myriad phenotypes, is a complex disorder with 
many interactions on genetic and mechanistic levels.  
2. Trisomic and non-trisomic genes 
2.1 The importance of trisomic and non-trisomic genes 
Numerous gene expression studies have been performed on an assortment of tissues from 
individuals with DS as well as mouse models of DS (Tables 2 and 3). Although these assays 
vary widely in technique and scope, they have generally focused on the altered expression 
of trisomic genes. A strict interpretation of the gene dosage hypothesis suggests that all 
trisomic genes theoretically exhibit a 1.5 fold upregulation in every tissue and cell when 
compared to normal subjects, and nearly all studies use this expected fold change as a 
standard for expression analysis (Giannone et al., 2004; Mao et al., 2003). Interestingly, in 
studies that have analyzed both trisomic and disomic (non-trisomic) gene expression in 
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trisomic compared to normal individuals, a significant number of non-trisomic genes have 
been found to be dysregulated in association with DS phenotypes (Table 4) (Lockstone et al., 
2007; Rozovski et al., 2007; Slonim et al., 2009). 
 
Study Strain Age Tissue Platform 
Chrast et al. 2000 Ts65Dn Adult Brain SAGE 
Saran et al. 2003 Ts65Dn 3-4 months Cerebellum Microarray 
Amano et al. 2004 Ts1Cje Postnatal 0 Brain Microarray 
Lyle et al. 2004 Ts65Dn Adult Brain, Heart, Kidney, Liver, 
Lung, Muscle 
qPCR 
Dauphinot et al. 2005 Ts1Cje Postnatal 0, 15, 30 Cerebellum Microarray 
Kahlem et al 2007 Ts65Dn 3-4 months Lung, Skeletal Muscle, 
Midbrain, Cerebellum, 
Cortex, Testis, Liver, Heart, 
Kidney 
Microarray 
Sultan et al. 2007 Ts65Dn 13-26 weeks Cerebellum, Midbrain, 
Cortex 
qPCR 
Laffaire et al. 2009 Ts1Cje Postnatal 0, 3, 7, 10 Cerebellum, Granule Cell 
Layer 
Microarray 
Moldrich et al. 2009 Ts1Cje E14 Neural Progenitor Cells Microarray 
Hewitt et al. 2010 Ts1Cje Adult Neural Stem Cells Microarray, 
qPCR 
Table 2. Features of gene expression assays performed in mice.  
 
Study Age Tissue Platform 
Gross et al. 2002 Gest. 16-24 weeks Placenta Microarray 
FitzPatrick et al. 2002 Fetal Amniocytes Microarray, qPCR 
Mao et al. 2003 Gest. 17-21 weeks Cerebral cortex, astrocytes Microarray 
Giannone et al. 2004 Adult T lymphocytes Microarray 
Tang et al. 2004 Adult Blood Microarray 
Chung et al. 2005 Fetal Amniocytes Microarray 
Deutsch et al. 2005 Adult Lymphoblastoids qPCR 
Mao et al. 2005 Fetal Cerebellum, heart Microarray 
Li et al. 2006 Gest. 15-23 weeks Heart, fibroblasts Microarray, qPCR 
Ait Yahya-Graison  
et al. 2007 
Adult Lymphoblasts Microarray 
Altug-Teber et al. 2007 Fetal Amniocytes,  
Chorionic Villus Cells 
Microarray 
Conti et al. 2007 Gest. 18-22 weeks Heart Microarray 
Lockstone et al. 2007 47-76 years Brain Microarray 
Prandini et al. 2007 25 years Lymphoblasts, Fibroblasts qPCR 
Rozovski et al. 2007 Fetal Placenta Microarray, qPCR 
Chou et al. 2008 Gest. 16-21 weeks Amniocytes Microarray 
Esposito et al. 2008 Gest. 19-21 weeks Frontal cortex Microarray 
Sommer et al. 2008 
Slonim et al. 2009 
1-4 years 
Fetal 
Lymphocytes 
Aminocytes 
SAGE, qPCR 
Microarray 
    
Table 3. Features of gene expression assays from human derived tissues.  
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The number and variety of genes found to be dysregulated in response to trisomy seems to 
vary greatly in a spatiotemporal dependent manner, and provide evidence against the idea 
of a specific 1.5 fold dysregulation of trisomic genes in all tissue types (Mao et al., 2005; 
Potier et al., 2006; Sultan et al., 2007). Additionally, much of the variation in both trisomic 
and disomic gene expression in subjects with trisomy overlaps with the variation observed 
among normal individuals, which may limit the number of trisomic genes found to be 
differentially expressed (Prandini et al., 2007), and contribute to the variable phenotypes 
associated with DS (Chou et al., 2008). We therefore hypothesize that both trisomic and non-
trisomic genes are important for the origin and development of DS phenotypes.  
2.2 Gene expression studies in humans and mouse models of DS  
2.2.1 Altered expression of trisomic genes and the gene dosage hypothesis 
The gene dosage hypothesis and the proposed 1.5 fold increase in all trisomic gene expression 
have motivated much of the gene expression research of DS phenotypes. Assessment of gene 
expression in human fetal brain tissue and astrocyte cell lines taken at 17-20 weeks gestation 
revealed a general upregulation of trisomic gene expression, and seemed to agree with the 1.5 
fold change hypothesis (Mao et al., 2003). Analysis of brain tissue isolated from 13-16 week old 
Ts65Dn mice also identified a global upregulation of trisomic genes in the cerebellum, cortex, 
and midbrain, and the average fold changes of trisomic gene expression were 1.44, 1.37, and 
1.39, respectively, in Ts65Dn mice (Sultan et al., 2007). 
Yet, other studies suggest the global upregulation of trisomic genes in agreement with the 
gene-dosage hypothesis is likely not occurring in DS. Many studies indicate that not all 
trisomic genes are dysregulated in all trisomic tissues. Furthermore, several studies on 
trisomic tissues have demonstrated expression levels significantly different from the 
expected 1.5 fold increase, indicating that having three copies of a gene does not necessarily 
confer a 1.5 fold upregulation. For example, expression analysis of 99 genes in 6 different 
tissues (brain, heart, lung, kidney, liver, and muscle) in P30 and 11 month old Ts65Dn mice 
revealed that 37% of the trisomic genes were expressed at a 1.5 fold increase, 45% were <1.5 
increase, 18% >1.5 increase, and 9% were not significantly different from normal mice (Lyle 
et al., 2004). Additionally, only 15% and 29% of tested trisomic genes were found to be 
overexpressed in DS fetal hearts and cultured fibroblasts, respectively (Li et al., 2006). Of 134 
differentially expressed genes assessed in lymphoblastoid cell lines (LCLs), 58/134 had 
overexpression greater than 1, (1.25-2.27), and 86/134 exhibited fold changes significantly 
different from 1.5 (9 were greater than 1.5 fold (1.64-2.27) and 77 were less than 1.5 (0.74-
1.4)) (Ait Yahya-Graison et al., 2007). Of 117 trisomic genes in LCLs and 114 trisomic genes 
in fibroblasts, only 39% and 62% respectively were found to have significant expression 
differences from euploid cells (Prandini et al., 2007). Based on these data, four classes of 
genes in trisomic tissues have been suggested: those that exhibit expression significantly 
different from 1 but not different from 1.5 fold, amplified genes (expression significantly 
greater than 1.5 fold), compensated genes (expression significantly less than 1.5 fold), and 
the genes with expression differences not different from 1 or 1.5 fold (Ait Yahya-Graison et 
al., 2007; Prandini et al., 2007). These extensive studies indicate that a global 1.5 fold 
upregulation of all trisomic genes in DS tissues is unlikely and suggest that mechanisms in 
addition to trisomy are also affecting gene regulation. Although the expression levels of 
some trisomic genes fit within the theoretical 50% upregulation, trisomic genes in several 
tissues at different time points exhibit expression levels much different from the expected 
1.5 fold increase.  
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Table 4. Significant trisomic and disomic genes highlighted by gene expression studies. 
Common genes of interest were selected from studies that stated more than three genes. 
N/A= not applicable or available. 
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2.2.2 Altered expression of non-trisomic genes 
While many gene expression studies have focused on expression levels of genes in three 
copies, increasingly the expression of non-trisomic genes has also been analyzed. Two early 
microarray studies using amniotic fluid and placenta found extreme variation associated 
with the genes on Hsa21, however both of these studies showed that disomic genes also 
contained high variation in expression in trisomic tissue (Chung et al., 2005; Deutsch et al., 
2005). It was observed that two-copy genes were downregulated implying that Ts21 was 
affecting genes on other chromosomes (Chung et al., 2005). An additional microarray 
analysis on cells derived from DS fetal placenta found 750 genes were overexpressed with 
the majority located on chromosomes other than 21, implicating non-trisomic genes as 
significant contributors to DS phenotypes (Rozovski et al., 2007). Adult human DS brains 
exhibited 400 differentially expressed genes when compared to normal individuals and 
approximately 350 of these were not found on Hsa21 (Lockstone et al., 2007). Expression 
analyses conducted on uncultured DS amniotic fluid cells identified a total of 414 
dysregulated genes with only five located on Hsa21 (Slonim et al., 2009). Two recent 
analyses of cells from developing Ts1Cje brains have also indicated a large number of 
dysregulated non-trisomic genes in addition to significantly dysregulated trisomic genes 
(Laffaire et al., 2009; Moldrich et al., 2009). Additionally, 6.5% of all disomic genes were 
found to be dysregulated in the primary neural progenitor cells isolated from the brains of 
adult DS mice (Hewitt et al., 2010). Based on these findings, it has been suggested that 
trisomy causes a disruption in gene regulation throughout the entire genome and not just of 
the genes in three copies. Despite these findings, the phenotypic effects of altered disomic 
gene expression in DS is highly debated and not well understood (Lyle et al., 2004; Mao et 
al., 2005; Saran et al., 2003). 
2.3 Measuring gene regulation with tissue and age specificity  
The most tissue-specific developmental microarray research in mouse models of DS has 
focused on the developing cerebellum, which continues to develop after birth. Extensive 
microarray analyses of the hypocellular cerebellum in adult and early postnatal trisomic 
mice have revealed dysregulation of both trisomic and non-trisomic genes. For example, 
microarray analyses were performed on the entire cerebellum during postnatal days 0, 15, 
and 30 (P0, P15, P30) in the Ts1Cje model of DS. Though genes present in three copies had 
an average relative expression of about 1.5 fold, only five (P0), nine (P15), and seven (P30) 
three copy genes of the 63 trisomic genes tested were expressed at levels >2 or <1.2. 
Additionally, 406 of 8250 two copy (non-trisomic) genes examined had ratios comparing 
trisomic and euploid expression that were significantly different from 1 (Dauphinot et al., 
2005). Three trisomic genes were dysregulated at all developmental time points. 
Interestingly, changes in development influenced gene expression differences between 
stages more than between trisomy and euploid animals (Dauphinot et al., 2005; Potier et al., 
2006). As these studies showed, gene expression can vary greatly in one tissue from early in 
development to adulthood. Because individual genes are shown to have variation in 
expression throughout development, certain genes may be relevant to a particular 
phenotype at one time point and unrelated at another. 
2.4 Gene expression variation in response to Trisomy 21 
In addition to the importance of understanding the temporal and spatial relationships 
associated with trisomic gene expression, variation in gene expression of both disomic and 
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trisomic genes may contribute to DS phenotypes. Expression studies conducted on fibroblasts 
and LCLs identified large gene expression variation between cell lines as well as between 
individual genes (Ait Yahya-Graison et al., 2007; Deutsch et al., 2005; Prandini et al., 2007). It 
was suggested that high levels of gene expression variation could explain why the majority of 
Hsa21 genes were not significantly upregulated and the variability in DS phenotypes. The 
latter is explained by the level of overlap between gene expression in trisomic and euploid 
individuals. Genes with distinct expression profiles may be candidates for the constant 
features of DS, whereas the genes that exhibit overlapping expression profiles may be 
responsible for the variable DS phenotypes (Prandini et al., 2007). 
Studies conducted in Ts65Dn mice also exhibited differing levels of variable gene 
expression. Sultan et al. showed that 31 out of 33 trisomic genes were upregulated in the 
Ts65Dn brain. Of these 31 genes, 24 genes exhibited a small amount of variation (coefficient 
of variation of <0.2) and seven genes exhibited high variation. These authors suggested that 
the level of variation in gene expression indicated how tightly the genes were being 
regulated in the brain tissue of Ts65Dn animals.  
Understanding gene expression variation in trisomic tissues is a key component in the study 
of DS gene-phenotype relationships. This expression variation may influence the results of 
microarray and qPCR studies and lead to the false identification/exclusion of candidate 
genes for specific phenotypes. Additionally the phenotypic variability observed in 
individuals with DS may be attributed to trisomic gene expression variation in different 
tissues, and it is likely that the level of variation within an individual gene is directly related 
to how tightly that particular gene is regulated. Further research is needed to identify the 
exact role expression variation plays in the development of DS phenotypes. 
2.5 Summary 
Gene expression assays in DS are an essential tool for understanding the mechanisms 
behind Ts21. While the gene dosage hypothesis may be applicable to specific genes with  
spatiotemporal specific expression, gene expression analyses suggest that not all trisomic 
genes are dysregulated at a 1.5 fold ratio, the expression of some trisomic genes is similar to 
euploid, and variation in gene expression plays a significant role in influencing phenotypic 
development. Differences in developmental stages as well as particular tissue types may 
contribute to some of the variable findings across studies. Additionally, the level of gene 
expression variation differs between individuals of the same genotype, adding to the 
complexity of understanding expression analyses. Though trisomic genes are important and 
are the likely initiators of DS phenotypes, disomic genes are also dysregulated suggesting 
that both trisomic and disomic genes can influence the DS phenotype.  
3. Complex genotype-phenotype relationships 
Characterization of certain DS phenotypes along with the genetic analysis of individuals 
with partial trisomies led to a hypothesis of the “Down syndrome critical or chromosomal 
region” (DSCR) believed to contain the genes necessary for the development of the most 
common phenotypes observed in individuals with DS (Delabar et al., 1993; Korenberg et al., 
1990). The sequencing of Hsa21 and mapping of specific genes in the putative DSCR further 
defined the genetic content of the region and allowed for a more detailed trisomic gene-
phenotype correlation. More recent analyses of critical regions using mouse models of DS as 
well as samples from individuals with partial trisomies have questioned the validity of the 
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original DSCR hypothesis of a single region or gene important for most of the common DS 
traits (Korbel et al., 2009; Lyle et al., 2009; Olson et al., 2004a). Current data suggest a single 
critical region or critical gene is not sufficient to cause multiple characteristic DS 
phenotypes. Rather, specific genes within susceptibility regions may play important roles in 
the establishment and maintenance of specific, but not all, DS phenotypes.  
3.1 Origins of the Down syndrome critical region hypothesis 
The DSCR was originally hypothesized based on the assessment of a family with partial 
Hsa21 trisomy and the variable expression of several of the characteristic physical features 
of DS. A “critical region” within 21q22 was believed to be responsible for several DS 
phenotypes including craniofacial abnormalities, congenital heart defects of the endocardial 
cushions, clinodactyly of the fifth finger and mental retardation  (Niebuhr, 1974). Soon after 
the DSCR hypothesis, genetic analyses of the Hsa21 DNA revealed several gene-rich 
segments located within 21q22 and placed further emphasis on this region as critical to the 
development of DS phenotypes (Brahe et al., 1990).  
The hypothesis of a DSCR shifted the focus of many in the DS research community toward 
understanding how these genomic regions could correlate with the development of DS 
phenotypes. Regions linked to congenital heart defects (CHD), duodenal stenosis and 
craniofacial abnormalities in individuals with DS were identified through further analyses 
(Korenberg et al., 1992). An analysis of ten patients with partial trisomy for different 
segments of Hsa21 led to the mapping of 24 DS phenotypes to six chromosomal regions. Of 
these 24 phenotypes, 13 were mapped to 21g22.2 – proximal 21q22.3 region and six were 
linked to the D21S55-MX1 region (Delabar et al., 1993). CHD was not included in the 
phenotypes associated with the D21S55-MX1 region, and a later assessment of 19 
individuals led to the mapping of CHD to a region outside of the D21S55-MX1 region on 
21q22.3 including DSCAM, a gene known to be involved in cell adhesion and expressed in 
the heart during development (Barlow et al., 2001a). A similar experiment comparing gene 
overlap regions with the phenotypic traits of 16 individuals with partial Ts21 along with the 
phenotypic variability observed in DS led to the hypothesis that factors in addition to 
trisomic genes both within and outside the DSCR likely contribute to most DS phenotypes, 
as opposed to a single critical region (Korenberg et al., 1994). Several additional genetic 
aspects including allelic heterogeneity, epistatic interactions, imprinting effects, 
uncharacterized epigenetic modifications and environmental events as well as the general 
variability observed in non-affected individuals were also suggested to have an impact on 
phenotypic variability (Korenberg et al., 1994).  
The DSCR hypothesis, derived from analyses of the shortest region of overlap in individuals 
with partial Ts21, paved the way for the establishment of gene-phenotype relationships 
associated with DS. However, the high variability in phenotypic expression caused by an array 
of trisomic genetic consequences severely restricts the resolution of the gene-phenotype 
relationships associated with DS. The sequencing of Hsa21 as well as the development of 
several mouse models of DS provided further insight into the DSCR hypothesis.  
3.2 Disproving the DSCR with mouse models 
Unlike the analyses of partial trisomy in humans, comparisons of DS mouse models with 
differing segmental aneuploidies (both on their own and crossed between each other) has 
allowed for a systematic and meticulous analysis of the relationship between certain 
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chromosomal regions and DS phenotypes. The Ts1Rhr/Ms1Rhr mouse model was created 
by generating a 3.9 Mb reciprocal duplication/deletion containing 33 genes (Cbr1-Orf9) 
homologous to those found in the most commonly recognized putative human DSCR 
(Olson et al., 2004a). Human DS-like phenotypes documented in Ts65Dn and Ts1Cje mice, 
which contain larger segmental trisomies, and the creation of Ts1Rhr and Ms1Rhr mice, 
established a system suitable to test the DSCR hypothesis in mice. Ts65Dn mice are smaller 
in size with shorter femurs and exhibit craniofacial abnormalities including smaller skulls 
and mandible bones, as well as brachycephaly when compared to euploid littermates—
defects  also found in humans with DS and previously attributed to the DSCR (Delabar et 
al., 1993; Richtsmeier et al., 2000). Analysis of Ts1Rhr mice revealed significant increases in 
overall size, length of femur, and mandible size when compared to euploid littermates and 
an absence of brachycephaly, indicating major differences between Ts1Rhr and Ts65Dn or 
Ts1Cje phenotypes (Olson et al., 2004a). Mice generated from a cross between Ts65Dn and 
Ms1Rhr mice (removing triplication of the DSCR in the Ts65Dn mouse) exhibited 
craniofacial phenotypes similar to those observed in Ts65Dn mice (Olson et al., 2004a). 
Comparison of the craniofacial phenotypes observed in Ts1Rhr and Ts65Dn/Ms1Rhr mice 
indicated that the DSCR is not sufficient to produce these phenotypes in DS mouse models, 
but may still contribute in the genetic context of the phenotypes observed in Ts65Dn mice 
through genetic interactions.  
In addition to the studies conducted on craniofacial skeletal abnormalities, DS-associated 
brain phenotypes have also been compared in DS mouse models. Ts65Dn mice exhibit a 
similar sized brain and hippocampus but smaller cerebellum and reductions in granule and 
Purkinje cell density when compared to euploid littermates (Baxter et al., 2000). Ts1Cje and 
Ms1Cje/Ts65Dn mice exhibit similar but less severe defects to those observed in Ts65Dn 
mice (Olson et al., 2004b). Analysis of Ts1Rhr mice revealed a similar sized brain and 
hippocampus when compared to euploid littermates, analogous to what was observed in 
Ts65Dn and Ts1Cje mouse models. The cerebellum of Ts1Rhr mice exhibited a small but 
significant reduction in size compared to euploid mice, but no differences were found in 
granule or Purkinje cell density, suggesting that trisomy for the DSCR is not sufficient to 
produce some brain phenotypes associated with DS (Olson et al., 2007). 
Furthermore, studies have shown that Ts65Dn mice exhibit impairment of hippocampal 
function similar to that observed in individuals with DS (Holtzman et al., 1996; Reeves et al., 
1995). Based on the DSCR hypothesis, genes within this region control the cognitive 
impairment phenotype associated with DS. If this were true, Ts1Rhr mice should exhibit 
similar deficits to Ts65Dn mice in hippocampal function. In contrast to Ts65Dn mice, Ts1Rhr 
exhibited normal hippocampal function in the Morris water maze test and normal induction 
of  long term potentiation (LTP) in the CA1 suggesting the DSCR is not sufficient to cause 
the cognitive impairment associated with DS (Aldridge et al., 2007; Olson et al., 2007). 
Interestingly, when three copies of the DSCR were reduced to two, Ts65Dn/Ms1Rhr mice 
performed similarly to euploid animals in the water maze test suggesting that although the 
DSCR is not sufficient on its own to cause cognitive impairment, it is necessary for the 
phenotype to occur (Olson et al., 2007).  
It is important to note that there are background differences between Ts65Dn, Ts1Cje, Ms1Rhr, 
and Ts1Rhr mice utilized in the studies described above. Inbreeding strategies for Ts65Dn 
and Ms1Rhr mice have not been successful, and these mice are maintained on an ~50% B6 and 
50% C3H advanced intercross genetic background. The majority of studies previously 
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documented in Ts1Rhr mice used a mixed background of approximately 50% B6, 25% 129 and 
25% C3H (except for the Morris water maze and LTP study where Ts1Rhr were on a B6 
background) and it is possible that background differences may cloud direct comparisons 
between these mouse models. Behavioral and neurophysiologic phenotypes were assessed in 
Ts1Rhr mice maintained on a ~50% B6 and 50% C3H background to mimic the same genetic 
background as Ts65Dn mice. In contrast to what was observed in Ts1Rhr mice on other 
backgrounds, these mice exhibited several (20 of 48) similar neurologic phenotypes as Ts65Dn 
mice suggesting that the DSCR may be sufficient to confer some characteristic DS cognitive 
and brain abnormalities (Belichenko et al., 2009). The differences in neurological phenotypes in 
Ts1Rhr mice on different genetic backgrounds suggest the importance of understanding the 
complex genetic interactions associated with DS. Although evidence in mouse models implies 
that there is no single region critical to the majority of DS phenotypes, it is apparent that a gene 
or genes within this region are important in certain phenotypes and these phenotypes may be 
dependent on genetic background. Either allelic differences associated with trisomic genes or 
other two-copy genes in the genome may be responsible for the differences observed between 
trisomies with different genetic backgrounds. 
3.3 New views on the DSCR and additional analyses in humans 
Advancements in DNA technology as well as additional individuals identified with partial 
trisomy have led to more information on the hypothesized DSCR and gene-phenotype 
relationships in individuals with DS. A genotype-phenotype correlation analysis conducted on 
30 individuals with either partial trisomy or partial monosomy for Hsa21 using array 
comparative genome hybridization found that four individuals with partial trisomy for the 
proximal portion of Hsa21 (not including the putative DSCR) exhibited several DS phenotypes 
(Lyle et al., 2009). Additionally, it was shown that there are multiple regions necessary to 
produce the cognitive impairment  and hypotonia associated with DS, as well as a region 
previously identified as a candidate for CHD (D21S3-PFKL) (Barlow et al., 2001a). These new 
results suggest that the concept of one chromosomal region important for the majority of DS 
phenotypes does not exist due to multiple genetic regions critical for DS phenotypes. Due to 
the identification of multiple regions contributing to the same phenotypes, these regions may 
be more aptly termed “susceptibility” regions and may correspond to one or a limited number 
of phenotypes (Lyle et al., 2009). Individuals with triplication of these genes are more likely to 
exhibit the DS phenotypes associated with these regions.  
High-resolution genetic mapping to determine gene involvement of eight specific DS 
phenotypes using 30 individuals with segmental trisomy for Hsa21 also concluded that 
specific genetic regions may be important for certain DS phenotypes. Genomic analysis 
revealed that the interaction of DYRK1A and RCAN1, thought to be involved in many DS 
phenotypes (Arron et al., 2006), were not essential in the development of CHD and mental 
retardation because individuals without trisomy for these genes exhibited severe 
abnormalities (Korbel et al., 2009). Additionally, several DS phenotypes, including transient 
myeloproliferative disorder, AMKL, and cognitive impairment, require triplication of 
multiple Hsa21 regions and genes (Korbel et al., 2009). A combination of data from this 
work and that in mouse models led to the specification of a CHD-causing region smaller 
than but included in a previously defined region for CHD (Barlow et al., 2001a). The newly 
defined region contains only 10 genes including DSCAM, a cell adhesion molecule highly 
expressed in the developing heart, also believed to contribute to the high levels of 
Hirschprung disease associated with DS (Korbel et al., 2009; Korbel et al., 2007).  
www.intechopen.com
 
Genetics and Etiology of Down Syndrome 78
Additional evidence against the synergy of DYRK1A and RCAN1 in causing craniofacial and 
cardiac abnormalities associated with DS (Arron et al., 2006; Richtsmeier et al., 2000) came 
from a family with a 4.3 Mb duplication of chromosome 21q22 (including DYRK1A but not 
RCAN1 or DSCAM). Individuals with the duplication presented with severe DS-like 
craniofacial abnormalities, but other malformations including cardiac defects were not 
observed. Based on these observations, the authors suggested two distinct regions important 
for these DS phenotypes with the distal region containing the genes including DYRK1A  
associated with craniofacial abnormalities and the proximal region (including RCAN1 and 
DSCAM) associated with cardiac abnormalities (Ronan et al., 2007).  
Interestingly, studies of individuals without DS provide evidence against the theory of only 
these distal and proximal specific regions associated with DS phenotypes. A patient with 
Silver-Russell syndrome, which has little similarity with DS, and his healthy father 
displayed a 0.46 Mb duplication of 21q22 including the RCAN1 gene. No DS-associated 
phenotypes were documented in either individual suggesting that RCAN1 alone is not 
sufficient to produce DS phenotypes (Eggermann et al., 2010). Furthermore, a child with a 
non-mosaic ring chromosome 21 duplication containing most of the long arm of Hsa21 
including the hypothesized DSCR was found to have several characteristic DS phenotypes 
including cardiac and gastrointestinal defects but lacked the usual facial features associated 
with DS (Crombez et al., 2005).  
Taken together, these studies provide evidence against the original DSCR hypothesis. It has 
been shown that genes and regions of genes located both within and outside of the 
hypothesized DSCR are critical to the initiation and severity of specific DS phenotypes. 
Studies conducted on humans with DS, DS mouse models, and other transgenic models 
have uncovered that several genes found within the putative DSCR are known to have a 
major effect on DS phenotypes. Thus, although the DSCR concept as traditionally defined 
does not seem to be correct, there are critical genes within this region that have a major 
impact on specific DS phenotypes. 
3.4 Individual genes associated with the DSCR 
Although it is evident the DSCR does not contribute to all of the phenotypes associated with 
DS, because the DSCR has been heavily studied, several genes found within this region have 
been implicated as candidate genes for individual DS phenotypes. The most extensively 
studied genes found within this region are Regulator of calcineurin1 (RCAN1/DSCR1) and 
dual specificity tyrosine-phosphorylation kinase 1a (DYRK1A), which are hypothesized to 
play important roles in several developmental pathways, including CNS, craniofacial 
skeletal and cardiac (Arron et al., 2006; Park et al., 2009; Richtsmeier et al., 2000). DYRK1A 
and RCAN1 are both involved in the regulation of NFAT, a critical transcription factor 
necessary for the processes of vertebrate development and organogenesis (Graef et al., 2001). 
Transgenic Nfatc mutant mice exhibit several characteristics similar to DS mouse models as 
well as humans with DS including cognitive impairment and craniofacial and cardiac 
abnormalities. Mice with overexpression of Dyrk1a and Rcan1 exhibited similar phenotypes 
to Nfatc mutants, suggesting that these genes are likely playing a part in the development of 
DS phenotypes (Arron et al., 2006).  
In addition to DYRK1A and RCAN1, Down syndrome cell adhesion molecule (DSCAM) has 
been suggested to play a critical role in the developing brain and has also been identified as 
a candidate gene for the increased levels of CHD observed in DS individuals (Alves-
Sampaio et al., 2010; Barlow et al., 2001a; Barlow et al., 2002). DSCAM is a critical factor in 
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neural differentiation, axon guidance, and the establishment of neural networks and it has 
been suggested that the disruption of these processes contributes to the DS neurocognitive 
phenotype (Agarwala et al., 2001; Barlow et al., 2001b; Yamakawa et al., 1998). A recent 
study found that Dscam was overexpressed in hippocampal neurons of the Ts1Cje mouse 
model. Overexpression of Dscam impaired dendritic branching leading to an inhibitory 
effect on synaptogenesis and neurite outgrowth, further implicating the role of Dscam in the 
development of the DS brain phenotype (Alves-Sampaio et al., 2010).  
Also found within the DSCR, ETS2 is a transcription factor known to be involved in the 
regulation of cellular proliferation, differentiation, transformation and apoptosis (Seth and 
Watson, 2005). Extensive studies on Ets2 in transgenic and DS mouse models have revealed 
that the gene may play a role in the neuronal, tumor suppressive, and craniofacial 
phenotypes associated with DS (Hill et al., 2009; Sussan et al., 2008; Wolvetang et al., 2003). 
Additionally, KCNJ6/GIRK2 overexpression in the hippocampus of Ts65Dn mice has been 
shown to cause an abnormal balance between inhibitory and excitatory synapses, 
implicating the gene in the DS-brain phenotype (Best et al., 2007). Additionally, this 
overexpression was also implicated in the reduced cerebellar size and alterations in granule 
cell neuron differentiation observed in the weaver mouse (Patil et al., 1995). 
3.5 Gene(s)-phenotype relationships 
The establishment of a specific phenotype requires the successful coordination of a number 
of genetic interactions. In many human disorders a single gene or gene network is 
responsible for causing the associated phenotypes. However, evidence from both humans 
and mouse models of DS suggests that specific DS phenotypes are influenced by genetic 
aberrations in multiple genes as opposed to a single gene. The most glaring case of multiple 
genes affecting a phenotype comes from the study of cognitive impairment through the 
analysis of human and mouse DS brains. DYRK1A, RCAN1, and DSCAM have all been 
shown to regulate the stages of neuronal cell maturation (proliferation, differentiation, and 
apoptosis) in the developing brain (Agarwala et al., 2001; Barlow et al., 2001b; Park et al., 
2010; Sun et al., 2011). Triplication of Olig1, Olig2, and Kcnj6, leads to significant changes in 
the ratio of inhibitory to excitatory neurons in the Ts65Dn forebrain (Best et al., 2007; 
Chakrabarti et al., 2010) and DSCAM regulates dendritic branching and neuronal network 
establishment (Alves-Sampaio et al., 2010), suggesting that increased inhibitory activity and 
the inability to form neuronal networks are also contributing to the cognitive impairment 
phenotype. In addition to cognitive impairment, an AD-like phenotype is apparent in most 
adult individuals with DS. Dysregulation of DYRK1A, RCAN1, and/or Ets2 lead to an 
increase in the number of neurofibrillary tangles and β-amyloid plaques in the brains of 
humans and mice (Ermak et al., 2001; Ryoo et al., 2008; Sun et al., 2011), respectively, 
indicating that multiple genes are contributing to the DS-AD phenotype. 
3.6 Summary 
Based on thorough analyses of studies on humans and DS mouse models, it is evident that 
there is not a single critical region of genes sufficient to cause all DS phenotypes. 
Alternatively, it is likely that there are multiple critical regions or critical genes contributing 
to a respective phenotype or group of phenotypes associated with DS (Lyle et al., 2009). 
Although studies conducted regarding the DSCR have provided a wealth of evidence 
refuting the idea, it is important to understand that several genes within this region have 
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been identified as key contributors to more specific DS phenotypes. Furthermore, both non-
trisomic genes and trisomic genes located outside of the hypothesized DSCR have also been 
implicated in the development of specific DS phenotypes and in some cases may be linked 
with DSCR associated genes. It is evident that DS phenotypes are influenced by a multitude 
of complex genetic interactions and it seems likely that multiple genes and gene networks 
will be involved in the development of most DS phenotypes. Important genes or regions of 
genes contributing to specific DS phenotypes should be defined as susceptibility genes or 
regions, as opposed to defining a single Down syndrome critical region or single gene-
phenotype relationship (Lyle et al., 2009).  
4. Functional analysis of genes 
4.1 Introduction 
Although hypotheses have been developed concerning cellular and developmental 
mechanisms relating to DS phenotypes, no conclusive evidence exists for a single 
mechanism likely responsible for the majority of DS phenotypes. Instead, multiple common 
mechanisms may be responsible for individual phenotypes in specific tissues or at precise 
developmental stages and groups of genes with related functions may also be dysregulated 
in DS pathology. Functional databases provide the foundation for elucidating gene-
phenotype relationships by clustering dysregulated genes with common functions. These 
clusters identify potential cellular, developmental and biological functions, as well as the 
number of genes in each cluster and significance of those categories. Depending on the 
functional annotation tool, relevant pathways, molecules for potential pharmacological 
interventions or insight into genetic mechanisms may be suggested. The use of functional 
databases extends the value of high throughput arrays and tests hypotheses that specific 
groups of genes with related function may be dysregulated in DS. Rather than a simple 
dosage increase of Hsa21 genes, it has been hypothesized that trisomy has a more global 
dysregulational effect on the genome, though developmental changes and tissue type do 
maintain a significant role (Altug-Teber et al., 2007; Dauphinot et al., 2005; Sommer et al., 
2008). We hypothesize that the interaction between trisomic and disomic genes have a 
significant effect on the way DS phenotypes arise, manifest and progress. 
Several studies have documented differential gene expression in unique spatial and 
developmental environments to determine mechanisms affecting DS phenotypes (Conti et 
al., 2007; Lyle et al., 2004; Moldrich et al., 2007). Other studies often concentrate on the 
cellular or developmental mechanisms as a causative factor of DS phenotypes (Chakrabarti 
et al., 2007; Contestabile et al., 2009; Cooper et al., 2001; Roper et al., 2006; Roper et al., 2009). 
High throughput analyses are important for investigating gene-phenotype relationships in 
analyses of various tissue and cell types from individuals with DS, mouse models of DS, and 
cell lines previously derived from individuals with DS or engineered to contain this extra 
genetic material. We hypothesize that a single generalized pathway or mechanism does not 
underlie the phenotypes of DS, but rather several pathways and mechanisms contribute to 
the phenotypes of DS, though some functional groups may cluster together in certain tissues 
or within phenotypes. Assessment of the gene-phenotype relationships in high throughput 
meta-analysis provides novel information regarding the importance of developmental 
processes in the DS pathophysiology. 
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4.2 Previously established functional analyses 
Studies of DS have utilized high throughput analysis on several tissues including cultured 
DS neural progenitor cells and tissue samples from DS amniocytes, hearts, cerebra and 
cerebella and cultured Ts1Cje neural progenitor cells (NPCs). Though differences are 
present between developmental time points and tissues, genes involved with cellular 
cycling, cell adhesion, signal transduction, DNA and RNA metabolism and binding, gene 
expression regulation and transcription, mitochondrial function and oxidative 
phosphorylation, kinase activity, and ECM production and maintenance were the most 
highly dysregulated and common categories observed, as well as maintain the ability to 
transcend time and tissue differences (Table 5). More specifically, certain cell types of 
representative models of DS or from individuals with DS share multiple common 
annotation results. We suggest a similar phenomenon may regulate multiple DS phenotypes 
in which dysregulated mechanisms affect the same tissue in order to produce a phenotype 
(Figure 1).  
4.2.1 Cell cycle alterations contribute to neurological phenotypes  
NPCs display altered gene expression related to cell cycling, proliferation, signaling, 
transcription and metabolism of chromosomal material. It is well established that deficits in 
proliferation and mitotic activity of specific cellular populations in the DS brain exist, 
including areas of the cerebellum and multiple areas of the cerebrum (Baxter et al., 2000; 
Chakrabarti et al., 2007; Gardiner et al., 2010; Roper et al., 2006). Additionally, impairment of 
proliferation in the cerebellum of fetuses with DS has also been reported (Guidi et al., 2010) 
as well as in the Ts65Dn neonate peripheral tissues and fibroblasts, suggesting a general 
deficit in proliferation as a mechanism for multiple DS abnormalities (Contestabile et al., 
2009). Individuals born with DS have reduced brain weights coupled with a smaller, 
dysmorphic skull and multiple cellular abnormalities within the brain including reduction 
in the number of neurons in the cerebral cortex as well as cellular deficiencies in multiple 
other structures (Aylward et al., 1997; Fink et al., 1975; Wisniewski, 1990). Therefore, these 
phenotypic deficits may be caused by a similar mechanism. However, downregulation of 
genes with proliferation-promoting function or upregulation of genes involved in the arrest 
of proliferation could equally, if not synergistically, contribute to the general proliferation 
deficit hypothesized to occur in several DS phenotypes. Overexpression of Dyrk1a in mouse 
NPCs was recently found to inhibit proliferation and stimulate precocious neuronal 
differentiation (Park et al., 2010; Yabut et al., 2010). DYRK1A has previously been implicated 
in the physiopathology of the cognitive impairment observed in individuals with DS 
(Altafaj et al., 2001; Smith et al., 1997) and is overexpressed approximately 1.5 fold in the DS 
and Ts65Dn brain (Dowjat et al., 2007; Guimera et al., 1999), suggesting upregulation of 
DYRK1A in concert with other Hsa21 and disomic genes in the DS brain may lead to deficits 
that underlie both cognitive phenotypes and other cellular phenotypes of DS. 
4.2.2 Changes in cell adhesion contribute to DS phenotypes  
In addition to brain, other tissues appear to be affected by alterations in cell homeostasis. 
Because cell cycling, cell adhesion, signal transduction, and ECM production all display 
dysregulation in DS fetal amniocytes, heart, cerebra and cerebella, one cannot conclude that 
a simple deficit in proliferation, such as that observed in DS skin fibroblasts (Kimura et al., 
2005), is sufficient to result in the DS phenotypes observed. While the DS brain is reduced in 
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size overall, it is also dysmorphic, pointing to both a decrease in proliferation, but perhaps 
also altered cell cycling, changes in the migratory pattern of progenitor cells and even the 
decreased founder population of these cells due to decreases in neurogenesis, implicating a 
complex interaction of mechanisms in the DS neurological phenotype (Bhattacharyya et al., 
2009; Guidi et al., 2010).  
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(Mao et al., 
2005) 
DS 
cerebrum 
 G     +  +    +   +   
Monovalent 
cation transport 
(Mao et al., 
2005) 
DS cerebe-
llum 
 G +          +      
Nerve impulses 
(Mao et al., 
2005) 
DS 
astrocytes 
 G +  +            + + 
 
(Mao et al., 
2005) 
DS heart 
 G +      +       +  + 
Cell-cell 
signalling 
(Conti et 
al., 2007) 
DS heart 
18-22 
wks 
G   22   9 48        8  
ATP synthesis, 
ECM, 
phosphate 
transport 
(Lockstone 
et al., 2007) 
DS dorso-
lateral 
prefrontal 
cortex 
 O  16 3 3 5   9 7 6   6    
Immune 
system, Notch 
and tryrosine 
signalling, cell 
migration, 
endocytosis 
(Rozovski 
et al., 2007) 
DS 
tropho-
blasts 
Fetal N 4     6           
Ubiquitine 
cycle, purine 
biosynthesis 
(Chou et 
al., 2008) 
DS amnio-
cytes 
16-22 
wks 
G   +  +       +     
 
(Esposito et 
al., 2008) 
DS NPCs 19-21 
wks 
I  25        20  25     
Molecular 
transport 
(Sommer et 
al., 2008) 
DS 
lympho-
cytes 
1-4 
yrs 
D 12 5    14       12    
Protein 
synthesis, 
kinase binding, 
antigen 
presentation 
(Bhattacha-
ryya et al., 
2009) 
DS NPCs 
 G  131  131    131 81        
Neurogenesis 
(Moldrich 
et al., 2009) 
Ts1Cje 
NPCs 
E14.5 G    75             
Development, 
homeostasis 
Table 5. Published functional analysis data for phenotypes of DS. Functional annotations 
were selected by lowest p-values for the categories established by the investigators and of 
specific interest to the authors. Studies are listed by tissue type and annotations are listed by 
most common to least common categories horizontally. Analysis tool abbreviations: G: 
GeneOntology (www.geneontology.org), I: Ingenuity Pathway Analysis 
(www.ingenuity.com), O: OntoExpress (vortex.cs.wayne.edu/projects.htm), N: NetAffex 
(www.affymetrix.com/analysis/index.affx), D: DAVID (david.abcc.ncifcrf.gov). 
In addition, approximately 50% of newborns with DS display a congenital heart defect, most 
of which involve septal and canal defects (Pediatrics, 2001). Previous studies have 
www.intechopen.com
 
Down Syndrome: A Complex and Interactive Genetic Disorder 83 
established a link between DS atrioventricular septal defects (AVSDs) and the importance of 
collagen VI in developing endocardial cushions (Baptista et al., 2000; Davies et al., 1995). 
Characterization of the involvement of collagen VI in cardiac development was later 
established when investigators observed altered collagen VI expression in AV endocardial 
cushions in the DS heart (Gittenberger-de Groot et al., 2003). Interestingly, genes encoding 
collagen VI are found on Hsa21 and its role as an extracellular matrix (ECM) component 
makes its presence ubiquitous throughout the body (Aumailley et al., 1991). A similar idea 
has recently been proposed in which atrioventricular canal (AVC) defects, which comprise 
the majority of congenital heart defects observed in DS, are a result of increased cell 
adhesion. Deficits in cell adhesion may lead to decreased cell migration to the ventricular 
canal because of changes in the ECM, leading to alterations in epithelial-mesenchymal 
transformations (Delom et al., 2009). Using a transchromosomic model of DS, investigators 
found both decreased cell migration and an increased affinity for adhesion to collagen VI 
(Delom et al., 2009). Importantly, differences in Hsa21 genes or groups of genes causing 
aberrations in both cellular properties may act in concert to lead to the development of AVC 
defects. It is therefore plausible that cell adhesion complexes coupled with ECM component 
alterations significantly contribute to congenital heart abnormalities in DS.  
In addition to congenital heart defects, individuals with DS are at an increased risk for 
dermatological disorders such as atopic dermatitis, causing susceptibility toward 
opportunistic infections (Madan et al., 2006). Studies utilizing DS skin fibroblasts have 
shown that these cells display an increased adhesion to collagen VI, likely leading to 
aberrant migration of these cells to target areas of the body (Jongewaard et al., 2002). This 
decreased migration would leave a smaller population of cells to make up an epidermal 
barrier and thus would compromise the integrity of the skin. Dysregulation of genes 
involved in cell adhesion may also lead to changes in junctional complexes that are found to 
be altered in functional analyses, and these changes may contribute to atypical migration of 
the cells with which they interact. 
4.2.3 Changes in DNA and RNA metabolism may lead to transcription and translation 
dysregulation 
Genes involved with the metabolism and expression of nucleic acids are highly 
dysregulated in multiple DS tissue types (brain, heart, trophoblasts) and time points in 
multiple functional analyses. The observed dysregulation of the genome due to the presence 
of the extra chromosomal material and its interaction with the rest of the genome is likely 
directed by multiple types of regulation. It may be that fewer transcripts are formed given a 
higher rate of metabolism of genetic material. The reduced transcripts directing cellular 
proliferation, migration or an anti-apoptotic state could lead to the smaller or altered 
structures observed in DS.  
In particular, changes in metabolism of genetic transcripts have been documented in the 
expression of multiple genes in both DS-related and unrelated tissues. Several studies 
sampling multiple DS-derived tissues have described the transcriptional alterations of 
Hsa21 genes, including two genes involved in nucleic acid metabolism: GART (purine 
metabolism) and ZNF294 (transcriptional regulation) (Lintas et al., 2010). DNA and RNA 
binding and metabolism may also be related to transcription factor activity, dysregulating 
genes downstream of these alterations. Alterations of transcription factors such as NFAT, as 
a result of dysregulation of DYRK1A and DSCR1, have the potential to lead to DS 
developmental phenotypes (Arron et al., 2006). The dysregulation of NFAT may initiate a 
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cascade of events affecting multiple downstream targets. Many of these genes may also be 
involved with cell cycling and maintenance as well as DNA and RNA binding and 
metabolism. Such studies, however, remain to be performed. 
4.2.4 Mitochondrial changes penetrate neurological and metabolic phenotypes 
The high incidence of mitochondria-related dysregulation in DS hearts, lymphocytes, and 
trophoblasts coupled with the increased prevalence of biomarkers of reactive oxygen species 
(ROS) in individuals with DS (Jovanovic et al., 1998) is an interesting and well-studied 
paradigm. Mitochondrial impairment in fetal hearts suggested by the downregulation of 
genes from five mitochondrial complexes, as well as the cerebellum and other brain regions, 
platelets, astrocytes and cultured fibroblasts suggests pervasive impairment of mitochondria 
in individuals with DS (Arbuzova et al., 2002; Busciglio et al., 2002; Conti et al., 2007; Kim et 
al., 2001; Kim et al., 2000; Prince et al., 1994). Interestingly, this mitochondrial impairment 
may affect other DS pathophysiology. Dysregulation of  the mitochondria has the ability to 
cause alterations in ATP synthesis, electron transport, monovalent cation transporter 
activity, oxidative phosphorylation, and general changes in physical components (Conti et 
al., 2007) (all found as dysregulated functional groups in Table 5). Furthermore, changes in 
membrane potential caused by this dysregulation may lead to increased mitochondrial 
susceptibility to other insults, leading to a constant feedback in the balance of genetic 
regulation (Roat et al., 2007). Two genes in particular located on Hsa21, SOD1 and BACH1, 
have been implicated the generation of ROS due to elevated H2O2 levels and decreased 
transcriptional activity, respectively. Elevated levels of SOD1 have been implicated in 
deposition of β amyloid and BACH1 downregulation has been proposed as a contributing 
mechanism to the development of Alzheimer disease neuropathology (Percy et al., 1990; 
Shim et al., 2003). High levels of oxidative stress in the brains of individuals with DS may 
indicate that dysregulation of normal processes in the mitochondria lead to anomalies 
including Alzheimer pathology (de Haan et al., 1997; Lockstone et al., 2007). A 
disproportionate number of ROS, caused by mitochondrial and other changes, combined 
with altered metabolism and feedback mechanisms suggest the complexity of  the 
interacting mechanisms involved in DS phenotypes affecting the brain, heart and skin 
(Busciglio and Yankner, 1995; Li et al., 2006; Sinha, 2005).  
4.3 DAVID analysis of trisomic genes in humans with DS and DS mouse models  
DS mouse models have the ability to predict phenotypes not previously observed in 
individuals with DS (Baxter et al., 2000; Pennington et al., 2003). We hypothesized that by 
analyzing the genes trisomic genes on Hsa21 as well as their homologs in two DS mouse 
models, we would observe common mechanisms as found by functional analysis of altered 
gene expression. Using DAVID (http://david.abcc.ncifcrf.gov/) we analyzed trisomic genes 
from Hsa21 and the Ts1Rhr and Ts65Dn mouse models 
(http://chr21.molgen.mpg.de/HSA21db.html). Functional annotations were obtained using 
the protocol described by Huang et al. 2009.  
Our analyses of Hsa21 genes revealed dysregulation of functional annotations including 
keratin, intermediate filament/cytoskeleton digestion, protein dimerization, interferon 
receptor activity, cytokine receptor activity, multiple junctions, cell adhesion, ionic channels 
and ECM (Table 6). Analysis of the genes triplicated in Ts65Dn mice revealed dysregulation 
of genes involved in ion transport, voltage-gated channels,  ionic channels, monovalent 
inorganic cation transport, tight junctions, calcium dependent cell-cell adhesion, regulation 
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of transcription, DNA binding, behavior, neuron development, neuron differentiation and 
synaptic transmission and cell-cell signaling. Analysis of genes in three copies from the 
Ts1Rhr mouse model identified functions integral to binding and related to regulation of 
transcription factor activity, transcription and DNA binding as the most enriched categories 
with the lowest p-values.  
As predicted, some, but not all functional groups found in previous analyses were also seen 
in our DAVID analysis. Data compiled using DAVID analysis of Hsa21 and two DS mouse 
models provide insight into what mechanisms appear to be generally dysregulated when 
trisomy for these regions occurs. Ts65Dn mice display many similarities to individuals with 
DS with regard to general brain, behavior, stature, heart and craniofacial phenotypes. 
Interestingly, a high level of overlap in functional categories also exists between the two 
analyses. For example, our analysis of Hsa21 and Ts65Dn revealed dysregulation of genes 
involved in cell adhesion, tight junctions and ionic transport. Ts65Dn mice replicate some of 
the heart defects observed in DS, and aberrant cell adhesion and migration have been 
implicated in these defects (Delom et al., 2009; Moore, 2006; Williams et al., 2008). Ts1Rhr 
and Ts65Dn triplicated genes led to functional hits in transcription, transcription factor 
activity, and RNA/DNA binding. While Ts1Rhr and Ts65Dn mice display some similar 
phenotypes, Ts1Rhr mice exhibit a number of phenotypes contrary to those seen in DS. It is 
noteworthy, though, that though these functional groups are dysregulated, they may be 
regulated in a manner divergent from one another, such as higher levels of transcription and 
RNA/DNA binding in Ts1Rhr than Ts65Dn, leading to the exaggerated phenotypes which 
Ts1Rhr mice display. Interestingly, no functional groups overlapped between the Hsa21 and 
Ts1Rhr analyses and this result provides additional evidence for the different phenotypes 
observed between humans with DS and this mouse model. Clearly, the involvement of other 
trisomic genes as well as disomic genes plays an important role in the identification of 
functional categories. Given that our analyses only included trisomic genes, it seems 
plausible that significant overlap between the past and current studies was not found. 
   
 
Table 6. DAVID analysis of trisomic genes from Hsa21 and Ts65Dn and Ts1Rhr mice. 
Functional annotations are listed in columns by most common dysregulated annotations, 
then by highest to lowest enrichment score and smallest to largest p-value in succession for 
each category. 
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4.4 Summary 
Functional analyses of genetic information for DS have the potential to revolutionize our 
understanding about the gene-phenotype relationships in DS (Ait Yahya-Graison et al., 
2007; Gardiner, 2010). Our meta-analysis of current functional analyses has indicated that 
cell cycling, maintenance, function, and adhesion, as well as DNA and RNA metabolism and 
binding and mitochondrial function are leading common mechanisms underlying DS 
phenotypes. The combination of multiple genes to produce specific disorder-related 
phenotypes appears to be a common theme in DS phenotypes. Groups of genes may act in 
concert to produce one or more phenotypes, or contribute a key factor in the development 
or maintenance of a phenotype. In many cases, functional groups and mechanisms overlap 
between tissues of different origins, but no general mechanism appears to be ubiquitously 
dysregulated amongst the tissues studied (Figure 1).  
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Fig. 1. Overlap of dysregulated functional groups occurs between multiple tissues, but no 
single mechanism appears to be dysregulated among all tissues studied. 
5. Conclusions 
Although the initial genetic insult is known and the phenotypes related to DS have been 
characterized, the relationship between genes and phenotypes has not been well 
distinguished for most DS phenotypes. Though phenotypes associated with DS must be 
caused by Ts21, high throughput gene expression analyses demonstrate the dysregulation of 
both trisomic and non-trisomic genes in tissues that are important for traits associated with 
Ts21. Hypotheses concerning critical regions and genes, thought to be important in most of 
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the major phenotypes associated with DS, have been disproved. Instead, it is postulated that 
a region of Hsa21 may be critical for a specific phenotype and a genomic region may contain 
a gene that is important (but not exclusive) for the causation of the trait. Moreover, there 
may be singular genes that are important in many, but not all, phenotypes associated with 
DS. Functional analyses of differentially expressed genes and genes in three copies may be 
used to further understand the relationships between genes and phenotypes. A number of 
differentially expressed genes may be tied into a mechanism and there may be mechanisms 
that are critical to a number of phenotypes. Thus, more accurate genotyping, large scale 
gene expression meta-analysis and functional mechanism investigations are helping to 
define gene-phenotype relationships in this complex and interactive disorder.  
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